If you are wondering what the next move should be for Roche Holding stock, you are not alone. Plenty of investors are watching carefully right now as Roche stages something of a comeback. Over the last week, shares have bounced up 3.8%, continuing a longer rally that has pushed the stock almost 10% higher in the past month. While that might sound like growth is back on the menu, it comes after a tougher few years, with the 3-year return sitting at -6.6% and the 5-year trailing by -3.4%. So, why all the renewed interest?
Recent developments in global pharma policy are definitely playing a part. U.S. tariffs on Swiss pharmaceutical imports have continued to dominate headlines, with talks between Swiss government officials and Roche taking center stage. The uncertainty around these tariffs has weighed on sentiment but the situation also opens up an opportunity if things resolve favorably. Meanwhile, Roche’s ability to respond quickly to regulatory changes, such as resuming shipments of important drugs for rare diseases, keeps confidence high among investors looking for resilience.
Now, when it comes to valuation, Roche looks more interesting than ever. Out of six major yardsticks analysts use to spot undervalued stocks, Roche ticks four, meaning it is checking the right boxes for value seekers. Still, there are strengths and blind spots in the classic valuation toolkit. Up next, I will break down these valuation checks in more detail, and later on, share an even better way to assess Roche’s true worth in today’s market.
Why Roche Holding is lagging behind its peers
The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future cash flows and discounting them back to today’s value. This reflects what those future streams are worth in the present. For Roche Holding, this involves looking at the expected cash Roche will generate in the future and then adjusting those amounts for the time value of money in Swiss Francs (CHF).
Currently, Roche generates Free Cash Flow (FCF) of approximately CHF 14.08 billion. Analyst estimates extend five years ahead, with projections such as CHF 16.28 billion in 2026 and CHF 20.54 billion in 2029. After that point, further forecasts are extrapolated and suggest Roche could reach about CHF 23.93 billion in annual FCF by 2035. All these figures are adjusted to present day value using an appropriate discount rate to capture risk and uncertainty.
Based on this method, the intrinsic value of Roche shares is estimated at CHF 776.89. Since this figure is 65.2% above the current share price, the DCF model suggests Roche is notably undervalued by the market at present.
Story Continues
Result: UNDERVALUED
ROG Discounted Cash Flow as at Sep 2025
Our Discounted Cash Flow (DCF) analysis suggests Roche Holding is undervalued by 65.2%. Track this in your watchlist or portfolio, or discover more undervalued stocks.
The Price-to-Earnings (PE) ratio is a time-tested way to value profitable companies like Roche Holding. It tells us how much investors are willing to pay for each franc of earnings, which makes it a go-to benchmark when analyzing established leaders in the pharmaceuticals sector. The “right” PE ratio for a company depends a lot on its growth outlook and the risks it faces. Companies with higher expected growth and lower risk tend to trade at higher multiples.
Currently, Roche trades at a PE ratio of 24.36x, which puts it just below the pharmaceuticals industry average of 24.71x. Interestingly, its major peers trade at a much loftier average of 71.36x. This suggests investors elsewhere in the sector may be paying a much steeper price for earnings growth. However, simply comparing Roche’s PE to the industry or its peers does not capture the whole story, since every company is unique in its growth trajectory, profitability, and risk profile.
This is where Simply Wall St’s “Fair Ratio” comes in. The Fair Ratio, calculated at 36.88x for Roche, adjusts for factors like future earnings growth, profit margins, industry dynamics, risk, and market cap. This makes it a more accurate way to judge whether the current PE is justified. Since Roche’s actual PE is well below this custom benchmark, it suggests that the market is undervaluing Roche’s earning power relative to its potential and sector context.
Result: UNDERVALUED
SWX:ROG PE Ratio as at Sep 2025
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.
Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is your personal story behind a company, linking your view of Roche’s business future, such as what you believe about its revenue, earnings, and margins, to a tailored financial forecast and fair value estimate.
Instead of just relying on ratios, Narratives help you connect the “why” behind the numbers with what those numbers could mean for the share price. They make the investment process more accessible, letting you see the bigger picture and update your view as new data arrives, like news or quarterly results. You can easily create or explore Narratives in the Simply Wall St Community, where millions of investors already share and improve their outlooks.
Narratives are especially useful when markets are uncertain, as they let you directly compare your fair value (based on your assumptions) to the current price, helping you decide when to buy or sell with conviction. For example, one Roche Narrative expects a fair value as high as CHF438.0 if innovations keep succeeding, while another sees a much lower fair value of CHF230.0 if challenges persist. This allows you to pick the story and numbers that best fit your own research and instincts.
Do you think there’s more to the story for Roche Holding? Create your own Narrative to let the Community know!
SWX:ROG Community Fair Values as at Sep 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.swx.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com